Интерлейкин 10 (ИЛ-10)

Interleukin-10 (IL-10) testing measures a key anti-inflammatory cytokine involved in immune regulation. The assay is used with other biomarkers to profile immune activity in acute and chronic infections and in severe inflammatory conditions, to investigate immune dysregulation associated with malignant neoplasms, and to track inflammatory trajectories after myocardial infarction or stroke. In the transplant setting, IL-10 can support assessment of allograft rejection risk when interpreted alongside complementary cytokines and cellular immune data. In gerontology, serial IL-10 results help document age-related shifts in immune competence. Results are interpreted within the full clinical and laboratory context.

Cytokines are protein mediators produced by blood and tissue cells—monocytes, macrophages, granulocytes, and lymphocytes—that orchestrate host defense against antigens and infection. They act predominantly through short-lived, local signaling at very low concentrations, binding to receptors on neighboring cells to trigger downstream responses. Interleukin-10 (IL-10) belongs to the anti-inflammatory cytokine group (including IL-4 and TGF-β) that modulates adaptive immunity and constrains excessive inflammatory reactions. IL-10 production is tightly regulated by other cytokines and is context dependent. IL-4 and IL-13 stimulate IL-10 synthesis. Interferon-γ (IFN-γ) inhibits IL-10 production in lipopolysaccharide-activated monocytes, yet IL-1, IL-2, IL-3, IL-6, IL-7, IL-12, IL-15, tumor necrosis factor-α (TNF-α), and IFN-γ can induce IL-10 across multiple cell types, including monocytes as well as T, B, natural killer, and mast cells. Functionally, IL-10 exerts potent anti-inflammatory, immunomodulatory, and immunosuppressive effects: it suppresses excess production of proinflammatory cytokines (IL-1α, IL-1β, IL-6, IL-8, IL-12, TNF-α, granulocyte-macrophage colony-stimulating factor, and IFN-γ) by activated macrophages and T helper 1 cells, while enhancing T helper 2 activity and the secretion of their cytokines (IL-4 and IL-10), effectively shifting the response from TH1 to TH2. IL-10 also autoregulates by downregulating its own mRNA expression. Because it is widely expressed and broadly immunosuppressive, IL-10 influences numerous disease states, including inflammatory disorders, autoimmunity, angiogenesis, and transplant rejection. In oncology, IL-10 has dual effects: elevated IL-10 may favor tumor emergence via immune suppression, yet IL-10 also inhibits angiogenesis by reducing macrophage-derived mediators (IL-1β, TNF-α, IL-6, and matrix metalloproteinase-9), thereby limiting tumor growth and metastasis. IL-10 can dampen early antimicrobial responses but protects against hyperinflammation and collateral tissue injury. In allergic conditions such as asthma and rhinitis, IL-10 production is reduced and correlates with disease severity. Measurement of IL-10 is used to investigate immune processes in severe inflammatory diseases, bacterial infections, and malignant tumors.